IT201700068009A1 - Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson - Google Patents

Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson

Info

Publication number
IT201700068009A1
IT201700068009A1 IT102017000068009A IT201700068009A IT201700068009A1 IT 201700068009 A1 IT201700068009 A1 IT 201700068009A1 IT 102017000068009 A IT102017000068009 A IT 102017000068009A IT 201700068009 A IT201700068009 A IT 201700068009A IT 201700068009 A1 IT201700068009 A1 IT 201700068009A1
Authority
IT
Italy
Prior art keywords
parkinson
strains
disease
treatment
composition
Prior art date
Application number
IT102017000068009A
Other languages
English (en)
Inventor
Giovanni Mogna
Original Assignee
Probiotical Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiotical Spa filed Critical Probiotical Spa
Priority to IT102017000068009A priority Critical patent/IT201700068009A1/it
Priority to KR1020207001745A priority patent/KR20200020850A/ko
Priority to US16/624,136 priority patent/US20200171106A1/en
Priority to CA3067305A priority patent/CA3067305A1/en
Priority to CN201880040409.2A priority patent/CN110891430A/zh
Priority to EP18740308.4A priority patent/EP3641568B1/en
Priority to BR112019026963-0A priority patent/BR112019026963A2/pt
Priority to PCT/IB2018/054509 priority patent/WO2018234995A1/en
Publication of IT201700068009A1 publication Critical patent/IT201700068009A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IT102017000068009A 2017-06-19 2017-06-19 Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson IT201700068009A1 (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT102017000068009A IT201700068009A1 (it) 2017-06-19 2017-06-19 Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson
KR1020207001745A KR20200020850A (ko) 2017-06-19 2018-06-19 파킨슨 질환을 처치하기 위한 락토바실러스 살리바리우스 종에 속하는 박테리아 균주를 포함하는 조성물
US16/624,136 US20200171106A1 (en) 2017-06-19 2018-06-19 Composition comprising bacterial strains belonging to the species lactobacillus salivarius for the treatment of parkinson's disease
CA3067305A CA3067305A1 (en) 2017-06-19 2018-06-19 Composition comprising bacterial strains belonging to the species lactobacillus salivarius for the treatment of parkinson's disease
CN201880040409.2A CN110891430A (zh) 2017-06-19 2018-06-19 用于治疗帕金森病的包含属于唾液乳杆菌物种的细菌菌株的组合物
EP18740308.4A EP3641568B1 (en) 2017-06-19 2018-06-19 Composition comprising bacterial strains belonging to the species lactobacillus salivarius for the treatment of parkinson's disease
BR112019026963-0A BR112019026963A2 (pt) 2017-06-19 2018-06-19 composição compreendendo cepas bacterianas per-tencendo às espécies lactobacillus salivarius para o tratamento de mal de parkinson
PCT/IB2018/054509 WO2018234995A1 (en) 2017-06-19 2018-06-19 COMPOSITION COMPRISING BACTERIAL STRAINS OF THE LACTOBACILLUS SALIVARIUS SPECIES FOR THE TREATMENT OF PARKINSON'S DISEASE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000068009A IT201700068009A1 (it) 2017-06-19 2017-06-19 Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson

Publications (1)

Publication Number Publication Date
IT201700068009A1 true IT201700068009A1 (it) 2018-12-19

Family

ID=60182930

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000068009A IT201700068009A1 (it) 2017-06-19 2017-06-19 Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson

Country Status (8)

Country Link
US (1) US20200171106A1 (it)
EP (1) EP3641568B1 (it)
KR (1) KR20200020850A (it)
CN (1) CN110891430A (it)
BR (1) BR112019026963A2 (it)
CA (1) CA3067305A1 (it)
IT (1) IT201700068009A1 (it)
WO (1) WO2018234995A1 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
CN113288920B (zh) * 2021-06-10 2023-03-28 吉林省农业科学院 大麻二酚单体与植物乳杆菌dp189联合在制备预防和/或治疗帕金森病药物中的应用
CN113559129B (zh) * 2021-08-18 2023-07-28 唐颐控股(深圳)有限公司 通过细菌治疗帕金森病的纳米装甲防护单细胞制品及其制备方法
CN115089557A (zh) * 2022-05-07 2022-09-23 天津大学 促进菌体在肠道产生gaba的层层自主药物、制备方法及应用
CN115581685A (zh) * 2022-09-08 2023-01-10 天津大学 一种多层共聚物包裹益生菌的时空定位装置制备方法
CN115887504B (zh) * 2022-09-16 2024-03-26 江南大学 长双歧杆菌ccfm1029在缓解帕金森病中的应用
WO2025143685A1 (ko) 2023-12-26 2025-07-03 주식회사 리스큐어바이오사이언시스 류코노스톡 팔켄버젠세 lbmb321010 균주 및 이를 포함하는 퇴행성 뇌질환의 예방, 개선 또는 치료용 조성물
KR102798366B1 (ko) * 2024-03-18 2025-04-18 명지대학교 산학협력단 L-티로신으로부터 레보도파를 생산하는 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010298A1 (en) * 2001-07-26 2003-02-06 Alimentary Health Limited 'probiotic lactobacillus salivarius strains
WO2004003235A2 (en) * 2002-06-28 2004-01-08 Puleva Biotech, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
WO2006102536A2 (en) * 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
WO2015170159A1 (en) * 2014-05-05 2015-11-12 Giovanni Mogna A composition for use in treating or preventing viral or bacterial infections in a subject undergoing anti-tumor chemotherapy, leukemia treatment or aids therapy comprising l. reuteri ler03 and/or l. salivarius ls06.
WO2017025936A2 (en) * 2015-08-13 2017-02-16 Probiotical S.P.A. Composition of lactic bacteria for use in the treatment of infections due to propionibacterium acnes and in particular for acne

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101087972B1 (ko) * 2009-11-24 2011-12-01 일동제약주식회사 치매, 치매관련 질환의 예방/치료 및 인지기능장애 개선에 효과가 있는 유산균 발효 산물, 이의 제조방법 및 용도
ES2384798B1 (es) * 2011-10-19 2013-06-04 Universidad De Granada Uso de melatonina para el tratamiento y/o prevención de la mucositis.
MX367109B (es) * 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
ITUB20155700A1 (it) * 2015-11-18 2017-05-18 Probiotical Spa Composizioni con azione sinergica tra un complesso gelificante muco-aderente contro il passaggio degli antigeni, e batteri immunomodulanti anti-IL17 per uso nel trattamento delle malattie autoimmuni e neurodegenerative IL17 dipendenti.
ITUA20164065A1 (it) * 2016-06-01 2017-12-01 Probiotical Spa Composizioni in gel per applicazioni topiche a base di batteri, preparazione delle stesse e loro usi.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010298A1 (en) * 2001-07-26 2003-02-06 Alimentary Health Limited 'probiotic lactobacillus salivarius strains
WO2004003235A2 (en) * 2002-06-28 2004-01-08 Puleva Biotech, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
WO2006102536A2 (en) * 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
WO2015170159A1 (en) * 2014-05-05 2015-11-12 Giovanni Mogna A composition for use in treating or preventing viral or bacterial infections in a subject undergoing anti-tumor chemotherapy, leukemia treatment or aids therapy comprising l. reuteri ler03 and/or l. salivarius ls06.
WO2017025936A2 (en) * 2015-08-13 2017-02-16 Probiotical S.P.A. Composition of lactic bacteria for use in the treatment of infections due to propionibacterium acnes and in particular for acne

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRAGO L ET AL: "Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: A randomized placebo-controlled study", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 24, no. 4, 2011, SAGE PUBLICATIONS INC. ITA, pages 1037 - 1048, XP002778674, ISSN: 0394-6320 *
MAZZINI L ET AL: "Theme 10 Therapeutic Strategies: TST-01 Potential role of gutmicrobiota in ALS pathogenesis", AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION -28TH INTERNATIONAL SYMPOSIUM ON ALS/MND, vol. 18, no. Supplement 2, 1 November 2017 (2017-11-01), TAYLOR AND FRANCIS LTD NLD, pages 245 - 260, XP002778675, ISSN: 2167-9223, DOI: 10.1080/21678421.2017.1374612 *
PEREZ-PARDO PAULA ET AL: "The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 817, 23 May 2017 (2017-05-23), pages 86 - 95, XP085268480, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2017.05.042 *

Also Published As

Publication number Publication date
BR112019026963A2 (pt) 2020-07-07
US20200171106A1 (en) 2020-06-04
WO2018234995A1 (en) 2018-12-27
CN110891430A (zh) 2020-03-17
EP3641568C0 (en) 2026-01-28
EP3641568A1 (en) 2020-04-29
EP3641568B1 (en) 2026-01-28
CA3067305A1 (en) 2018-12-27
KR20200020850A (ko) 2020-02-26

Similar Documents

Publication Publication Date Title
PH12020550660A1 (en) Cultivation of placenta to isolate exosomes
EP3641568C0 (en) Composition with bacterial strains of the genus Lactobacillus salivarius for the treatment of Parkinson's disease
ME03424B (me) Kompozicije koje sadrže bakterijski soj blautia hydrogenotrophica za upotrebu u liječenju bakterisjkih infekcija gastrointestinalnog trakta
CO2020007142A2 (es) Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus
MX2022000056A (es) Peptidos anti-microbianos estabilizados.
IL265528A (en) aav therapy for Huntington's disease
ME03487B (me) Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
EP3562514A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE
MY188541A (en) Besifloxacin for the treatment of resistant acne
NZ630117A (en) Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same
PL3240403T3 (pl) Kompozycje mikrobiologiczne i sposoby zastosowania w celu sprzyjania wzrostowi roślin i leczeniu chorób roślin
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
IT1398553B1 (it) Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
NZ727392A (en) Methods of preparing substituted nucleotide analogs
EP3285776A4 (en) METHOD FOR TREATING BACTERIAL INFECTIONS
ZA202002093B (en) Antibacterial compounds
EP3402872A4 (en) MILKIC ACID USE BACTERIA GENETICALLY MODIFIED TO POLYSACCHARIDE-DERIVED ENZYMES
MX2016008221A (es) Composiciones prebioticas para el cuidado oral que contienen un alquilglucosido.
SMT201900692T1 (it) Composizione per l'uso del trattamento delle infezioni batteriche
PT3285787T (pt) Tratamento de infeções bacterianas em aquicultura
PT3856213T (pt) Métodos de tratamento de infeções utilizando bactérias
WO2015035234A3 (en) Anti-microbial compounds and compositions
PL3322480T3 (pl) Bakterie Lactobacillus w leczeniu zaburzeń czynności serca